Related Experiment Videos
CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease
P L Zinzani1, E Barbieri, M Bendandi
1Institute of Hematology, L. e A. Seràgnoli, University of Bologna, Italy.
Tumori
|December 31, 1994
Summary
The CEP chemotherapy regimen shows effectiveness in treating relapsed or resistant Hodgkin's disease, achieving complete remission in over half of patients. This approach can help reduce tumor burden before stem cell support.
Area of Science:
- Hematology
- Oncology
- Clinical Chemotherapy
Background:
- Advanced Hodgkin's disease often leads to relapse or incomplete remission after initial treatment.
- Approximately 50% of advanced Hodgkin's disease patients face relapse or failure to achieve complete remission.
Purpose of the Study:
- To evaluate the efficacy of CEP combination chemotherapy in patients with relapsed or refractory Hodgkin's disease.
- To assess the role of CEP in reducing tumor burden and determining chemosensitivity prior to stem cell transplantation.
Main Methods:
- Twenty-three patients with relapsed/resistant Hodgkin's disease received CEP chemotherapy (CCNU, etoposide, prednimustine).
- All patients had prior treatment with MOPP and ABVD regimens.
Main Results:
- A 56% complete response rate was observed with CEP chemotherapy.
- Four patients (18%) achieved partial response, with two converting to complete remission post-transplant.
- Complete remission was not affected by treatment timing or disease characteristics, but was influenced by primary refractory disease.
Conclusions:
- CEP is an effective regimen for Hodgkin's disease patients experiencing first or second relapse.
- CEP can be utilized to decrease tumor burden and assess chemosensitivity before stem cell support.